Diffusion Pharmaceuticals (DFFN) Reports Significant Progress in its Strategic Review Process
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
November 14, 2022 6:30 AM ESTDiffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process
Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital
LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Clients Offer
Company Believes LifeSci Proxy Campaign is Attempt to Circumvent Strategic Review Process
Date of Diffusions 2022 Annual Meeting of Stockholders Set for December 30, 2022
CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion... More
